The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.
Kurenkov A.L.
National Medical Research Center for Children’s Health
Kuzenkova L.M.
National Medical Research Center for Children’s Health
Bursagova B.I.
National Medical Research Center for Children’s Health
Klochkova O.A.
National Medical Research Center for Children’s Health
Chernikov V.V.
National Medical Research Center for Children’s Health
Kuznetsova M.A.
National Medical Research Center for Children’s Health
Ashrafova U.S.
National Medical Research Center for Children’s Health
Kuprianova O.S.
National Medical Research Center for Children’s Health
Botulinum toxin type A (Incobotulinum toxin A) in spastic forms of cerebral palsy: a retrospective analysis of clinical experience
Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(7): 68‑77
Views: 1876
Downloaded: 53
To cite this article:
Kurenkov AL, Kuzenkova LM, Bursagova BI, et al. . Botulinum toxin type A (Incobotulinum toxin A) in spastic forms of cerebral palsy: a retrospective analysis of clinical experience. S.S. Korsakov Journal of Neurology and Psychiatry.
2020;120(7):68‑77. (In Russ.)
https://doi.org/10.17116/jnevro202012007168
A retrospective analysis of the experience of using Incobotulinum toxin A injections for the treatment of spasticity in children with cerebral palsy (CP).
One hundred and eighty-five children with spastic forms of CP, including 114 boys (61,6%), were studied. The average age of the patients was 3,8±2,5 years; the average weight was 14,2±6,9. The patients received injections of Incobotulinum toxin A according to registered indications or recommendations of a consultation of specialists and voluntary informed consent of the patient’s representative. At least 1 point decrease of muscle tone according to the modified Ashworth scale was used as a criterion of the antispastic effect of Incobotulinum toxin A.
The total dose of Incobotulinum toxin A for the whole group of patients with CP was 154,5±67,7 U and 11,6±4,7 U per kg/body weight. The gracilis muscle (65,4% of cases, 95%CI 58,1—72,2) and the gastrocnemius muscle (49,4% of cases, 95%CI 41,8—56,6) were the most frequently injected targets in the lower extremities, and the pronator teres muscle (58,9% of cases, 95%CI 51,5—66,1) — in the upper extremities. Adverse events were observed in 13 patients (7,0%). They were mild in 9 patients and moderate in 4 patients.
Our data confirmed the effectiveness and safety of Incobotulinum toxin A injections in spastic CP. The calculated average doses of Incobotulinum toxin A for target muscles and the frequency of different spasticity patterns could serve as a reference for the botulinum therapy planning.
Keywords:
Authors:
Kurenkov A.L.
National Medical Research Center for Children’s Health
Kuzenkova L.M.
National Medical Research Center for Children’s Health
Bursagova B.I.
National Medical Research Center for Children’s Health
Klochkova O.A.
National Medical Research Center for Children’s Health
Chernikov V.V.
National Medical Research Center for Children’s Health
Kuznetsova M.A.
National Medical Research Center for Children’s Health
Ashrafova U.S.
National Medical Research Center for Children’s Health
Kuprianova O.S.
National Medical Research Center for Children’s Health
Received:
18.05.2020
Accepted:
20.05.2020
List of references:
Close metadata
Email Confirmation
An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.
Email Confirmation
Log in to the site using your account in one of the services
We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.